Table 1. Comparison of characteristics of cancer drug economic evaluation documents published by CADTH, NICE and PBAC.
| Characteristic | Economic evaluation documents, no. (%) | |||
|---|---|---|---|---|
| All (n=240) |
CADTH (n=114) |
NICE (n=65) |
PBAC (n=61) |
|
| ICD-10 cancer site | ||||
| C15–C26 digestive organs | 37 (15.4) | 15 (13.2) | 10 (15.4) | 12 (19.7) |
| C30–C39 respiratory and intrathoracic organs | 44 (18.3) | 21 (18.4) | 15 (23.1) | 8 (13.1) |
| C43–C44 melanoma and other malignant neoplasms of skin | 26 (10.8) | 14 (12.3) | 7 (10.8) | 5 (8.2) |
| C45–C49 mesothelial and soft tissue | 10 (4.2) | 4 (3.5) | 3 (4.6) | 3 (4.9) |
| C50–C50 breast | 42 (17.5) | 22 (19.3) | 10 (15.4) | 10 (16.4) |
| C51–C58 female genital organs | 18 (7.5) | 8 (7.0) | 3 (4.6) | 7 (11.5) |
| C60–C63 male genital organs | 20 (8.3) | 9 (7.9) | 5 (7.7) | 6 (9.8) |
| C64–C68 urinary tract | 27 (11.3) | 11 (9.7) | 9 (13.9) | 7 (11.5) |
| C69–C72 eye, brain and other parts of central nervous system | 6 (2.5) | 2 (1.8) | 2 (3.1) | 2 (3.3) |
| C73–C75 thyroid and other endocrine glands | 10 (4.2) | 8 (7.0) | 1 (1.5) | 1 (1.6) |
| Treatment setting | ||||
| Advanced/metastatic | 212 (88.3) | 98 (86.0) | 61 (93.9) | 53 (86.9) |
| Neoadjuvant/adjuvant | 28 (11.7) | 16 (14.0) | 4 (6.2) | 8 (13.1) |
| Data maturity (% death) | ||||
| <20% | 28 (11.7) | 17 (14.9) | 5 (7.7) | 6 (9.8) |
| 20%–50% | 79 (32.9) | 45 (39.5) | 17 (26.2) | 17 (27.9) |
| 50%–70% | 49 (20.4) | 23 (20.2) | 14 (21.5) | 12 (19.7) |
| >70% | 51 (21.3) | 20 (17.5) | 14 (21.5) | 17 (27.9) |
| NR | 33 (13.8) | 9 (7.9) | 15 (23.1) | 9 (14.8) |
| Reimbursement recommendation | ||||
| Negative | 55 (22.9) | 12 (10.5) | 14 (21.5) | 29 (47.5) |
| Positive | 185 (77.1) | 102 (89.5) | 51 (78.5) | 32 (52.5) |
| Substantial clinical benefit by the ESMO-MCBS | ||||
| No | 84 (35.0) | 38 (33.3) | 25 (38.5) | 21 (34.4) |
| Yes | 156 (65.0) | 76 (66.7) | 40 (61.5) | 40 (65.6) |
| Incremental QALYs, median (IQR) | 0.6 (0.4–1.1) | 0.6 (0.4–1.3) | 0.6 (0.3–1.0) | 0.5 (0.3–0.8) |
CADTH, Canada’s Drug and Health Technology Agency; ESMO-MCBS, European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; NICE, National Institute for Health and Care Excellence; NR indicates that the proportion of death was not reported; PBAC, Pharmaceutical Benefits Advisory Committee; QALY, Quality-adjusted life year.